12 Health Care Stocks Moving In Friday's After-Market Session

Benzinga · 06/12 21:05
Gainers
- Aspire Biopharma Holdings (NASDAQ:ASBP) stock moved upwards by 23.2% to $6.11 during Friday's after-market session. The market value of their outstanding shares is at $7.7 million.
- Innate Pharma (NASDAQ:IPHA) stock moved upwards by 19.31% to $2.1. The market value of their outstanding shares is at $163.2 million.
- Aditxt (NASDAQ:ADTX) shares increased by 12.59% to $0.01.
- Retractable Technologies (AMEX:RVP) shares rose 7.97% to $0.76. The market value of their outstanding shares is at $20.9 million.
- Aytu BioPharma (NASDAQ:AYTU) shares increased by 7.44% to $2.31. The market value of their outstanding shares is at $23.5 million.
- XORTX Therapeutics (NASDAQ:XRTX) shares rose 7.33% to $2.34. The market value of their outstanding shares is at $3.7 million.
Losers
- Cuprina Holdings (Cayman) (NASDAQ:CUPR) shares fell 9.4% to $3.6 during Friday's after-market session. The company's market cap stands at $6.4 million.
- Zhengye Biotechnology (NASDAQ:ZYBT) shares declined by 8.6% to $0.75. The market value of their outstanding shares is at $42.6 million.
- Adial Pharmaceuticals (NASDAQ:ADIL) shares fell 6.72% to $2.78. The company's market cap stands at $6.3 million.
- Autonomix Medical (NASDAQ:AMIX) shares decreased by 6.57% to $0.36. The market value of their outstanding shares is at $4.4 million.
- Theriva Biologics (AMEX:TOVX) stock fell 6.42% to $0.28. The company's market cap stands at $14.0 million.
- GlucoTrack (NASDAQ:GCTK) stock declined by 6.42% to $0.36. The market value of their outstanding shares is at $2.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.